Craig Williams | CEO-Partner, Flagship Pioneering; CEO
Apriori Bio

Craig Williams, CEO-Partner, Flagship Pioneering; CEO, Apriori Bio

Craig Williams joined Flagship Pioneering in 2023 and serves as CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori Bio.

Prior to Flagship, Craig spent more than two decades at GSK and ViiV Healthcare. During his time at GSK, Craig was charged with developing business strategies, managing operations and driving sales for vaccines and therapeutics globally, helping to launch over 15 vaccines and medicines around the world. He took on roles of increasing scope and complexity, including US Vaccines sales and marketing leadership roles, overseeing commercialization of vaccines and medicines in Africa and Southeast Asia, heading the company’s UK Respiratory business unit, and culminating in his most recent position as Global Vaccines Commercialization Lead where he led a cross-functional team responsible for the development and launch of vaccines across the company’s portfolio. Craig has also served as Head of ViiV International, in which he oversaw ViiV’s HIV business in nearly 150 countries.

Craig received both an MBA and B.A. from Florida A&M University School of Business & Industry.

Appearances:



Day 2 - Wednesday 1st April @ 17:10

Panel: Platforms Are Out, Products Are In: What VCs & Private Investors Really Want

    is panel will explore the shifting priorities in venture capital investment within the vaccine and biotech space. Historically, platforms promised broad, long-term innovation, but today’s market increasingly favors tangible, indication-specific products. Is this a cyclical trend or a fundamental shift? Join leading VCs as they debate the future of biotech funding, the role of hype, and what startups must do to attract investment in a more cautious, product-driven landscape.
  •     Understand the current VC investment climate in biotech and vaccines.
  •     Explore the tension between platform-based innovation and product-focused funding.
  •     Discuss how hype and market cycles influence valuations and investor interest.
  •     Provide actionable insights for startups seeking VC attention. 

last published: 11/Mar/26 19:15 GMT

back to speakers